mTOR的雷帕霉素不敏感伴侣蛋白(RICTOR)扩增定义晚期胃癌的一个亚组并对AZD2014介导的mTORC1/2抑制敏感
研究对640例转移性实体瘤患者肿瘤样本行二代测序(NGS)寻找分子靶点,NGS检出RICTOR扩增13例(2%),其中胃癌6例,胃癌中RICTOR扩增频率为3.8%(6/160)。FISH确认5/13例(38%)扩增,包括4例胃癌和1例肺癌。RICTOR扩增的患者来源细胞(PDC)对mTORC1/2抑制剂AZD2014表现出优先敏感性,RICTOR敲低可逆转该敏感性。
要点
- NGS检出RICTOR扩增13/640例(2%),其中胃癌6例,胃癌中频率为3.8%(6/160)。
- FISH确认RICTOR扩增5/13例(38%),包括4例胃癌和1例肺癌。
- RICTOR扩增PDC对mTORC1/2抑制剂AZD2014优先敏感,RICTOR敲低逆转该敏感性。
核心结论
- RICTOR扩增是实体瘤中罕见但具有治疗相关性的基因组改变。
- 结果支持在RICTOR扩增胃癌中进一步开展AZD2014的临床前和临床研究,并强调基因组分析的重要性。
研究设计与样本
- 前瞻性对640例转移性实体瘤患者(主要为胃肠道和肺癌)的肿瘤样本行NGS检测以识别分子靶点。
- NGS检出的RICTOR扩增样本用FISH确认。
- 建立RICTOR扩增的患者来源细胞(PDC)系,用于研究选择性AKT、mTORC1和mTORC1/2抑制的效果。
主要发现
- NGS检出13/640例(2%)RICTOR扩增肿瘤,包括6例胃癌、3例NSCLC、1例SCLC、1例CRC、1例肉瘤、1例MUO。
- 13例中7例经IHC显示RICTOR蛋白过表达。
- 胃癌中RICTOR扩增的NGS检出频率为3.8%(6/160)。
- FISH确认5/13例(38%)样本扩增(RICTOR/对照>2),包括4例胃癌和1例肺癌。
- RICTOR扩增PDC对选择性AKT抑制剂AZD5363、选择性mTORC1抑制剂依维莫司、双重mTORC1/2抑制剂AZD2014和多靶点激酶抑制剂帕唑帕尼的处理中,对mTORC1/2抑制剂AZD2014表现出优先敏感性;RICTOR敲低逆转PDC对AZD2014的敏感性。
关键数值与推荐
- RICTOR扩增定义为RICTOR/对照>2(FISH确认标准)。
- NGS检出RICTOR扩增13/640例(2%)。
- 胃癌中RICTOR扩增频率为3.8%(6/160)。
- FISH确认扩增5/13例(38%)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Targeting oncogenic genomic aberrations is an established therapeutic strategy in multiple tumor types. Molecular classification has uncovered a number of novel targets, and rapamycin-insensitive companion of mTOR (RICTOR) amplification has been identified in lung cancer. Further investigation assessing the therapeutic potential of RICTOR amplification as a novel target across advanced cancers is needed. PATIENTS AND METHODS: Tumor samples from 640 patients with metastatic solid tumors, primarily gastrointestinal and lung cancers were prospectively subjected to a next-generation sequencing (NGS) assay to identify molecular targets. Samples with NGS-detected RICTOR amplification were confirmed with FISH. A RICTOR-amplified patient-derived cell (PDC) line was generated and used to investigate the effectiveness of selective AKT, mTORC1, and mTORC1/2 inhibition. RESULTS: NGS identified 13 (2%) of 640 patients with RICTOR-amplified tumors (6 gastric, 3 NSCLC, 1 SCLC, 1 CRC, 1 sarcoma, 1 MUO). Of the 13 patients, seven patients had RICTOR protein overexpression by IHC. The prevalence of RICTOR amplification in gastric cancer by NGS was 3.8% (6/160). FISH testing confirmed amplification (RICTOR/control >2) in 5/13 (38%) of samples, including four gastric cancers and one lung cancer. Treatment of a RICTOR amplified PDC with a selective AKT (AZD5363), selective mTORC1 (everolimus), dual mTORC1/2 (AZD2014), and the multi-target kinase inhibitor pazopanib demonstrated preferential sensitivity to the mTORC1/2 inhibitor (AZD2014). Knockdown of RICTOR reversed PDC sensitivity to AZD2014, validating the importance of RICTOR amplification to the PDC line. CONCLUSIONS: RICTOR amplification is a rare but therapeutically relevant genomic alteration across solid tumors. Our results support further pre-clinical and clinical investigation with AZD2014 in RICTOR amplified gastric cancer and highlights the importance of genomic profiling.
引用
- Kim ST, Kim SY, Klempner SJ, et al. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition. Ann Oncol. 2017. PMID: 28028034. doi:10.1093/annonc/mdw669
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。